Terapi plasma exchange pada krisis miastenik
Abstract
Krisis miastenik adalah perburukan gejala yang terjadi pada pasien miastenia gravis, ditandai dengan kondisi gagal nafas. Sebanyak 15-20 % pasien miastenia gravis mengalami krisis miastenik dalam kehidupannya. Mortalitas akibat krisis miastenik pada saat ini mulai menurun, salah satunya adalah karena peran terapi plasma exchange (PE). Terapi PE dapat menghilangkan substansi seperti antibodi yang bersifat patologis, kompleks imun, dan sitokin, dari plasma, kemudian diganti dengan cairan pengganti. Pada laporan ini, kami membahas kasus seorang perempuan 21 tahun yang telah menderita miastenia gravis tipe okular (sejak tahun 2016), masuk ke unit gawat darurat dengan diagnosis krisis miastenik yang dipicu infeksi saluran nafas nafas atas. Pasien dirawat di unit perawatan intensif dan mendapat dukungan ventilator mekanikal, kemudian dilakukan tindakan terapi plasma exchange dengan hasil perbaikan luaran klinis.
Keywords
References
Ropper AH, Samuels MA. Adams and Victor’s Principles of Neurology Tenth Edition. Mc Graw Hill Medical. 2014;1470-83.
Hakim M, Susanti L, Arimbawa IK, Kurniani N. Miastenia gravis, dalam : Pedoman tatalaksana GBS, CIDP, MG, Imunoterapi. Jakarta. Penerbit Kedokteran Indonesia. 2018.
Lacomis D. Myasthenic crisis. Neurocrit Care. 2005;03:189-194.
Saunders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, et al. International consensus guidance for management of myasthenia gravis. Neurology. 2016;87;419-25.
Jose Americo M, Fernandes S, Jose IS. Neurocritical care of myasthenic crisis in Myasthenia Gravis and Related Disorder. Switzerland. Springer Nature. 2018;12:189-197.
Schwartz J, Padmanabhan A, Aqui N, Balogun R, Smith LC, Delaney M, et al. Guidelines on the use of therapeutic apheresis in clinical practice- evidence-based approach from the writing committee of the American society for apheresis. J Clin Apheresis. 2016;31:149-338.
Wendell LC, Levine JM. Myasthenia crisis. The neurohospitalist. 2011;1(1):16-22.
Sharma S, Lal V, Prabhakar S, Agarwal R. Clinical profile and and outcome of myasthenia crisis in tertiary care hospital: a perspective study. Ann Indian Acad Neurol. 2013;16(2):203-207.
Vern JC. Myasthenia gravis: management of myasthenic crisis and preoperative care. Semin Neurol. 2004;24:75-81.
Bershad EM, Feen ES, Suarez JI. Myasthenia gravis crisis. Southern Med Jour. 2008;101(1):63-9.
Ali SS, O’Connel C, Kass L, Graff G. Single breath counting: a pilot study of a novel technique for measuring pulmonary function in children. Am J Emerg Med. 2011;29:33-6
Kaminski JH. Treatment of myasthenia gravis in Myasthenia gravis and related disorders, Current clinical neurology, Third edition. Springer Nature. 2018;168-81.
Schroeter M, Thayssen G, Kaiser J. Myasthenia Gravis- Exacerbation and crisis. Neurol Intern Open. 2018;2:E10-5.
Ebadi H, Barth David. Safety of plasma exchange therapy in patients with myasthenia gravis. Musc Nerv. 2013;510-4.
Farmakidis C, Pasnoor M, Dimashkie M, Barohn RJ. Treatment of myasthenia gravis. Neurol Clin. 2018;36:311-37.
Mandawat A, Mandawat A, Kaminski HJ, et al. Outcome of plasmapheresis in myasthenia gravis: delayed therapy is not favorable. Muscle Nerve. 2011;43(4):578–84.
Katzberg HD, Barnett C, Bril V. Predictors of response to immunomodulation in patients with myasthenia gravis. Muscle Nerve. 2012;45:648-52.
Usmani A, Kwan L, Khalil DW, Trivedi J, Nations S, Sarode R. Excellent response to therapeutic plasma exchange in myasthenia gravis patients irrespective of antibody status. J Clin Apher. 2019;1-7.
Alemam AI, Abdulrahman AI. Seropositivity in myasthenia gravis as a predictor of response to therapeutic plasma exchange. J Neurol Res. 2019;9(1-2):8-13.
DOI: 10.24815/jks.v22i1.23336
Refbacks
- There are currently no refbacks.